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Preclinical evaluation of PAC1 
targeting with radiolabeled 
Maxadilan
Lieke Joosten1, Maarten Brom  1, Martin K. H. Schäfer2, Otto C. Boerman1, Eberhard Weihe2 
& Martin Gotthardt1
There is an ongoing search for new tracers to optimize imaging of beta cell-derived tumors 
(insulinomas). The PAC1 receptor, expressed by insulinomas, can be used for targeting of these 
tumors. Here, we investigated whether radiolabeled maxadilan could be used for insulinoma imaging. 
Maxadilan was C- or N-terminally conjugated with DTPA (termed maxadilan-DPTA or DTPA-maxadilan 
respectively). BALB/c nude mice bearing subcutaneous INS-1 tumors were injected with either In-111-
labeled maxadilan-DTPA or In-111-DTPA-maxadilan. Biodistribution studies were carried out at 1, 2 
and 4 hours after injection and SPECT/CT imaging 1 and 4 hours after injection of maxadilan-DTPA-111In. 
Radiolabeling of maxadilan-DTPA (680 MBq/nmol) was more efficient than of DTPA-maxadilan (55 MBq/
nmol). Conjugation with DTPA slightly reduced receptor binding affinity in vitro: IC50 values were 3.2, 
21.0 and 21.0 nM for maxadilan, natIn-DTPA-maxadilan and maxadilan-DTPA-natIn respectively. Upon 
i.v. injection maxadilan-DTPA-111In accumulated specifically in INS-1 tumors (7.30 ± 1.87%ID/g) and 
in the pancreas (3.82 ± 0.22%ID/g). INS-1 tumors were clearly visualized by small animal SPECT/CT. In 
conclusion, this study showed that the high affinity of maxadilan to the PAC1 receptor was maintained 
after DTPA conjugation. Furthermore, radiolabeled maxadilan-DTPA accumulated specifically in INS-1 
tumors and, therefore, may qualify as a useful tracer to image insulinomas.
The most common pancreatic neuroendocrine tumors (NETs) are insulinomas. Insulinomas are tumors derived 
from the insulin-producing beta cells located in the islets of Langerhans in the pancreas. Clinical symptoms 
include symptomatic hypoglycemias as well as weight gain (due to increased food intake to compensate for hypo-
glycemia) and neurological symptoms1. Biochemical diagnosis is based on low blood glucose levels or elevated 
proinsulin, insulin and C-peptide levels in plasma and these tests can be complemented with fasting tests (which 
result in hypoglycemia if insulinoma is present)1–3. The most widely used nuclear medicine imaging strategy for 
detecting insulinomas is somatostatin receptor scintigraphy (SRS) using 111In-labeled octreotide. SRS is based 
on targeting somatostatin receptors (SSTR), which are over-expressed in sixty percent of insulinomas4. Because 
the remaining forty percent has either low or no expression of this receptor, many insulinomas are not being 
detected by scintigraphy based on somatostatin receptor targeting2–4. More preferably, PET (Positron Emission 
Tomography) imaging with octreotide analogues can be used, since PET is more sensitive than SPECT imaging, 
due to the higher spatial resolution of clinical PET scanners and higher sensitivity in detection of emitted gamma 
photons. A few promising studies were conducted using SSTR PET/CT, although these studies showed that a 
small percentage of insulinomas remain undetected5–8.
More than ten years ago, it was demonstrated that almost all insulinomas express several neuropeptide recep-
tors, including CCK2 (cholecystokinin), VPAC1 (vasoactive intestinal peptide/PACAP receptor subtype 1) and 
GLP-1 (glucagon-like peptide 1) receptors4. Several preclinical SPECT and PET studies in RipTag2 mouse models 
using the GLP-1 analogues exendin-3 and exendin-4, showed specific tracer accumulation in insulinomas via the 
GLP-1 receptor9–11. In the first pioneering clinical PET/CT and SPECT/CT studies with exendin-4 in insulinoma 
patients, small insulinomas, which could not be detected by conventional imaging methods (endoscopic ultra-
sound, MRI (Magnetic Resonance Imaging), CT (Computed Tomography), SRS)12–17, were accurately diagnosed. 
The success of visualizing neuroendocrine tumors is partially dependent on the type of receptors expressed in the 
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tumors, as was shown previously by Baumann et al.5. For example, malignant insulinomas have a low incidence 
and expression density of the GLP-1 receptor, but show high expression of the somatostatin receptor, where in 
benign insulinomas the expression profile is more favorable for the GLP-1R4, 18, 19. Therefore, to improve the diag-
nostic tool box, the search for new tracers for detection of insulinomas is ongoing.
Vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase activating polypeptide (PACAP), and their 
receptors PAC1, VPAC1 and PAC2 have emerged as important factors in islet cell function (insulin secretion) 
and growth and differentiation of neuroendocrine tumors including insulinomas. As these receptors are highly 
expressed in insulinomas and beta cells, they are potential targets for beta cell and insulinoma imaging20–22.
Using in vitro receptor autoradiography with VPAC1 and VPAC2 subtype-selective ligands, respectively, insu-
linomas have been demonstrated to bind high levels of radiolabeled selective VPAC1 receptor ligands, although 
substantially less than GLP1 selective ligands4. As PAC1, VPAC1 and VPAC2 mRNAs were detected in a rat 
insulinoma cell line with PAC1 binding prevailing over that of VPAC1 and VPAC223, the PAC1 receptor seemed 
to be a promising alternative for targeting insulinomas. The natural mammalian ligands at the PAC1 receptor are 
PACAP38 and the truncated form PACAP27. They bind to PAC1, VPAC1 and VPAC2, whereas VIP only binds to 
VPAC1 and VPAC2. Since PACAP38 and PACAP27 are non-selective PAC1/VPAC1/VPAC2 ligands and unstable 
in plasma24, they are not suited for in vivo targeting of PAC1 receptors. More than two decades ago it was demon-
strated that the stable analogue maxadilan shared features with ligands of the PACAP family25, 26. Maxadilan is a 
61-amino acid vasoactive peptide, derived from sand flies27, 28, and has been demonstrated to bind specifically and 
with high affinity to the PAC1 receptor but not to either VPAC1 or VPAC228.
In the present study we have examined the ability of 111In-labeled maxadilan to image rat insulinoma xeno-
grafts (INS-1) in a nude mouse model. For this purpose maxadilan was either C- or N-terminally conjugated with 
DTPA to allow labeling with 111In. These compounds were evaluated for their radiolabeling properties and in vitro 
and in vivo binding characteristics.
Results
Radiolabeling. 111In-DTPA-maxadilan and maxadilan-DTPA-111In could be labeled with a specific activity of 
55 and 680 MBq/nmol, respectively. The radiochemical purity after purification exceeded 95%.
Serum stability. The stability of maxadilan-DTPA-111In was analyzed in human serum. The radiochemical 
purity directly after labeling was >95% (Fig. 1A). The radiolabeled peptide remained intact up to 24 hrs after 
incubation in human serum, as is shown in Fig. 1B. 111In-EDTA and radiolabeled maxadilan have a retention time 
of 3–4 min and 14.6 min, respectively.
Competitive binding assay. The results of the IC50 determination of labeled and unlabeled maxadilan ana-
logues are summarized in Fig. 2 and Table 1. Unlabeled maxadilan had the highest affinity (IC50 value: 3.2 nM) for 
the receptor. DTPA conjugation resulted in a somewhat lower affinity as indicated by slightly higher IC50 values: 
18.3 and 13.2 nM (p < 0.001 and p < 0.001) for DTPA-maxadilan and maxadilan-DTPA, respectively. Labeling of 
DTPA-maxadilan or maxadilan-DTPA with 115In did not significantly reduce the affinity (p = 0.07 and p = 0.12 
respectively) compared to the unlabeled compounds.
Biodistribution studies. The results of the in vivo PAC1 receptor targeting study with 111In-labeled 
maxadilan in BALB/c nude mice bearing subcutaneous INS-1 tumors are summarized in Fig. 3. Uptake 
Figure 1. Stability of maxadilan-DTPA-111In in human serum. (A) HPLC profile of maxadilan-DTPA-111In 
directly after labeling. (B) Stability analysis of maxadilan-DTPA-111In before and 1, 2, 4 and 24 h after incubation 
in human serum at 37 °C.
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Figure 2. Competitive binding assay (IC50) on INS-1 cells of unlabeled maxadilan, maxadilan-DTPA 
and DTPA-maxadilan, either unlabeled, or labeled with 115In. 111In-labeled maxadilan-DTPA was used as 
radioligand. The table shows the IC50 values in nM.
Peptide IC50 (nM)
95% confidence 
interval (nM)
Maxadilan 3.2 2.1–4.9
Maxadilan-DTPA 13.2 8.8–19.8
DTPA-Maxadilan 18.3 13.2–25.3
Maxadilan-DTPA- NatIn 21.0 13.7–32.2
NatIn-DTPA-Maxadilan 21.0 11.8–37.3
Table 1. IC50 values and 95% confidence interval (in nM) of the competitive binding assay on INS-1 cells.
Figure 3. Biodistribution of 111In-labeled DTPA-maxadilan and maxadilan-DTPA in BALB/c nude mice 
bearing subcutaneous INS-1 tumors. Values are expressed as a percentage of the injected dose per gram of tissue 
(n = 5 mice per group, error bars SD). Blocking was performed by coinjection of a 100-fold excess of unlabeled 
maxadilan. Mice were dissected 2 hours after injection.
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of maxadilan-DTPA-111In in the tumor was 7.76 ± 1.37%ID/g, which was significantly higher than that of 
111In-DTPA-maxadilan (4.82 ± 0.87%ID/g) (p = 0.0037). Also, pancreatic uptake was significantly higher 
for maxadilan-DTPA-111In compared to 111In-DTPA-maxadilan, (3.87 ± 0.56%ID/g and 2.73 ± 0.35%ID/g 
respectively, p = 0.0048). Accumulation in both tumor and pancreas could be blocked by an excess of unla-
beled maxadilan, demonstrating specific uptake of the peptides via the PAC1 receptor (1.54 ± 0.49%ID/g and 
1.24 ± 0.48%ID/g for maxadilan-DTPA-111In and 111In-DTPA-maxadilan respectively in tumor tissue and 
0.59 ± 0.07%ID/g and 0.43 ± 0.04%ID/g respectively for pancreatic uptake). Renal uptake was very high and 
similar for both peptides (148 ± 3 and 145 ± 19%ID/g for 111In-DTPA-maxadilan and maxadilan-DTPA-111In, 
respectively), which could not be blocked with an excess of unlabeled maxadilan. Furthermore, in all other 
dissected organs, except for blood and spleen, receptor-mediated uptake of maxadilan was observed. Since 
these results showed that maxadilan-DTPA-111In has higher accumulation in tumor and pancreatic tissue 
than 111In-DTPA-maxadilan, this peptide was used to study the pharmacokinetics. Figure 4 shows the fast 
clearance of the peptide from the blood. Furthermore, tumor accumulation peaked at one hour after injec-
tion (7.30 ± 1.87%ID/g) and decreased slightly over time (5.85 ± 1.17%ID/g and 5.49 ± 0.66%ID/g after 2 and 
4 hours (not significant)). A similar trend was observed for the uptake in the pancreas: 3.82 ± 0.22%ID/g at 1 h 
p.i., 2.71 ± 0.36%ID/g at 2 h p.i. and 2.55 ± 0.07%ID/g at 4 h p.i.. Renal uptake increased over time, while the 
specific accumulation in the liver decreased. Table 2 gives an overview of the tumor-to-normal-organ ratios for 
111In-labeled maxadilan-DTPA.
SPECT of BALB/c nude mice bearing subcutaneous INS-1 tumors. SPECT/CT images of BALB/c 
nude mice bearing subcutaneous INS-1 tumors are shown in Fig. 5.
Images were acquired one and four hours after injection of 111In-labeled maxadilan-DTPA and INS-1 tumors 
in the right shoulder were clearly visualized. In addition to tumor and kidney, accumulation of the tracer in the 
liver was observed. Figure 5C shows the image of a mouse which was co-injected with an excess of unlabeled 
maxadilan. The tumor on the right shoulder was not visualized with SPECT/CT, demonstrating specific uptake 
via the PAC1 receptor.
Discussion
We demonstrate here for the first time that indeed radiolabeled maxadilan is a promising new tool to image sub-
cutaneously transplanted insulinomas in mice.
We were able to radiolabel maxadilan with 111In with high specific activity while preserving the affinity for 
the PAC1 receptor. High and specific uptake of this tracer in both subcutaneous INS-1 tumors and pancreas was 
found. SPECT imaging clearly visualized the s.c. INS-1 xenografts. Both, pancreatic as well as tumor uptake were 
receptor mediated, as was demonstrated by blocking experiments with unlabeled maxadilan.
Since the conjugation of a DTPA moiety can affect the affinity of the peptide for the receptor, the peptide was 
conjugated with DPTA at either the C- or the N-terminus and the molecules were compared. The maximum 
specific activity of maxadilan-DTPA-111In was at least twelve times higher than that of 111In-DTPA-maxadilan. 
This could possibly be explained by hindrance of the radiometal incorporation into the DTPA molecule, due to 
either the secondary or tertiary structure of maxadilan or a conformational change in the peptide as a result of 
the conjugation.
Figure 4. Biodistribution of 111In-labeled maxadilan-DTPA in BALB/c nude mice bearing subcutaneous INS-1 
tumors. Values are expressed as a percentage of the injected dose per gram of tissue (n = 4 mice per group, error 
bars SD). Mice were dissected 1, 2 and 4 hours after injection to study the pharmacokinetics.
Time p.i. (h) Tumor-to-Blood Tumor-to-Muscle Tumor-to-Pancreas Tumor-to-Kidney
1 44.62 ± 10.63 11.45 ± 3.75 2.01 ± 0.35 0.06 ± 0.02
2 139.65 ± 24.28 10.59 ± 2.25 2.34 ± 0.35 0.04 ± 0.01
4 314.74 ± 40.82 11.83 ± 1.91 2.04 ± 0.23 0.04 ± 0.01
Table 2. Tumor-to-normal-organ ratios for 111In-labeled maxadilan-DTPA. Mean ± SD are shown.
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Conjugation of DTPA to either the C-or N-terminus of maxadilan influenced the receptor binding affinity 
significantly. Maxadilan contains four cysteine residues, which form two disulfide bridges, one of which is located 
close to the N-terminus. Furthermore, it is known that the N-terminal residues of maxadilan are important for 
receptor binding23, 29. Therefore, it was thought likely that conjugation of DTPA to the N-terminus could influ-
ence the binding affinity. However, it has also been shown in previous studies that when the disulfide bridge at 
the N-terminal part of maxadilan is removed or changed, the receptor binding capacity of maxadilan is pre-
served29, 30. Nevertheless, as was determined in our in vivo biodistribution studies, the C-terminally modified 
maxadilan-DTPA-111In analogue showed higher uptake in the tumor, therefore this compound was used for fur-
ther characterization.
The biodistribution shows specific accumulation of maxadilan in most organs. This is in line with the wide-
spread PAC1 receptor expression and function in the pituitary, adrenal medulla, pancreas, stomach, colon, lung, 
and heart31, 32. As demonstrated in the SPECT images, maxadilan-DTPA-111In clearly visualized the subcutaneous 
INS-1 tumors and they were easily distinguished from the specific accumulation of radiolabeled maxadilan in 
various other tissues.
Other preclinical studies using INS-1 tumour-bearing mice have shown that GLP-1 receptor targeting lig-
ands, labeled either with 111In, 68Ga or 18F, show a more favorable biodistribution compared to this maxadilan 
tracer. Although those previously-studied tracers show high tumor and kidney uptake similar to maxadilan, the 
tumor-to-normal-organ ratios are more optimal, which can be correlated with expression levels of the different 
receptors that are targeted9, 33, 34. Future studies need to be conducted to compare radiolabeled maxadilan with 
existing relevant PET agents in animals, before moving to clinical trials.
Recently, clinical imaging techniques such as 68Ga-labeled somatostatin receptor imaging and radiolabeled 
GLP-1 receptor imaging were introduced for diagnosis of insulinomas. These tracers would be useful for differen-
tiating benign from malignant tumors or in diagnosis of metastatic NETS. However, the sensitivity is not optimal 
and false positive or false negative cases continue to be described using somatostatin receptor targeting8, 19, 35. 
False negative-SSTR PET/CT could be explained by small lesions (missed because the resolution of the scanner 
is not sufficient to detect them) or low somatostatin receptor expression (leading to a low signal which cannot 
be detected as the sensitivity of the scanner is not sufficient). A solution to the latter problem would be the use 
of a combination of different radiotracers, thus targeting alternative receptors. This was also suggested by Reubi 
et al., who conducted an elegant in vitro study proving that a cocktail of three different ligands was able to detect 
all tested NETs36. Tumors with no or low receptor density, which would be missed in vivo when using only one 
radiotracer, have a higher probability of being detected when multiple receptors are targeted. In addition, if one 
of the tracers had a very high uptake in the tumor, this high uptake could help to overcome the limited spatial 
resolution and also visualization of small lesions.
In addition to diagnostic imaging, some somatostatin analogues, when radiolabeled with a beta emit-
ter, are used as therapeutic agents37. Due to the high accumulation of radiolabeled maxadilan in the kid-
neys, and to a lesser extent in other organs, the feasibility of peptide receptor radionuclide therapy with 
maxadilan would be questionable. Insulinomas may not be the only NETs in which radiolabeled maxadilan 
could play a diagnostic role. In a study carried out by Pisegna et al. high expression levels of the PAC1 recep-
tor in rat gastric ECL (enterochromaffin-like) cells were observed38, 39. Currently, 111In-DTPA-octreotide or 
68Ga-DOTATOC/68Ga-DOTA-octreotide are used for the detection of gastric neuroendocrine tumors, which 
Figure 5. Fused SPECT/CT images of BALB/c nude mice bearing subcutaneous INS-1 tumors on the right 
shoulder (green arrow), obtained one and four hours p.i.. Image of a mouse injected with 9 MBq of maxadilan-
DTPA-111In, 1 h (A), 4 h (B), and a mouse with 9 MBq of maxadilan-DTPA-111In and a 100 fold excess of 
unlabeled maxadilan (C). Kidneys are indicated with red arrows. Uptake in the abdomen is also seen, mainly in 
liver (A and B).
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originate from ECL cells40. Furthermore, PAC1 receptor expression has been demonstrated in Lewis lung tumour 
transplants41. Radiolabeled maxadilan could therefore be a possible candidate for detecting both ECL derived 
tumors and a subtype of small cell lung cancer, in addition to somatostatin receptor tomography. Moreover, there 
is evidence that there is high expression of PAC1 in human tumors such as paragangliomas, neuroblastomas, pitu-
itary adenomas and endometrial cancers42–45 with expression found also in human lung cancers46. Importantly, 
most of these studies were conducted in vitro, so in vivo studies are needed to explore the ratio between peptide 
uptake in PAC1 receptor positive tumors and that in normal tissues where PAC1 is widely expressed.
In conclusion, radiolabeled maxadilan accumulates efficiently and specifically in INS-1 tumors and could 
potentially be used for in vivo PAC1 targeting in patients with insulinoma. Radiolabeled maxadilan, therefore, 
represents a new tracer to image insulinomas using SPECT in addition to or in combination with octreotide 
and exendin for the identification of benign or malignant insulinoma. Furthermore, the expression of PAC1 in 
other human tumors indicates a broader application for the usage of radiolabeled maxadilan. Thus, the newly 
generated PAC1 selective high affinity radiopeptide maxadilan can be employed for multireceptor tumour tar-
geting in vivo.
Materials and Methods
Peptides. DTPA-conjugated and native maxadilan were purchased from Think Peptides (ProImmune 
Limited, Oxford, United Kingdom). N-terminal conjugation of DTPA (DTPA-Maxadilan) was performed with 
isothiocyanate-DTPA (Macrocyclics, Dallas, TX, USA) via a beta-alanine spacer and C-terminal conjugation 
(Maxadilan-DTPA) with p-NH2-Bn-DTPA via an extra C-terminal glutamic acid. The quality and purity of 
the peptides was determined using RP-HPLC (reversed-phase high performance liquid chromatography) and 
mass spectrometry (MS) by the manufacturer. RP-HPLC showed a purity of 95.35%, 93.9% and 100% and 
a retention time of 15.18 min, 15.81 min and 14.46 for maxadilan, DTPA-maxadilan and maxadilan-DTPA 
respectively. With MS the expected mass of the peptides was confirmed (6870, 7537 and 7641 Da for max-
adilan, DTPA-maxadilan and maxadilan-DTPA respectively). The amino acid sequences of the peptides are 
shown in Table 3.
Radiolabeling. DTPA-maxadilan and maxadilan-DTPA were labeled with 111In by adding 111InCl3 to 1 µg 
peptide in 0.1 M MES buffer, pH 5.5. After incubation at RT for 20 min, 50 mM EDTA (ethylenediaminetetraacetic 
acid) (Sigma Aldrich, St. Louis, MO, USA) was added to a final concentration of 5 mM. Quality control was per-
formed by Instant Thin Layer Chromatography (ITLC) on silica gel ITLC strips (Pall Corporation Life Sciences, 
New York, NY, USA). As a mobile phase 0.1 M EDTA in 0.1 M NH4Ac, pH 5.5 was used (Rf 111In-maxadilan = 0, 
Rf 111In-EDTA = 1). The reaction mixture was purified on a disposable PD-10 desalting column (GE Life Sciences, 
Diegem, Belgium), which was eluted with 10 ml PBS, 0.5% (v/w) bovine serum albumin (BSA) and fractions 
containing radiolabeled maxadilan were pooled.
Serum stability. Maxadilan-DTPA was labeled with 5 MBq 111InCl3 as previously described and incubated 
with human serum (1:10) at 37 °C. Before addition of human serum and 1, 2, 4 and 24 hrs after incubation with 
human serum, samples were taken, mixed with acetonitrile (1:1) and centrifuged for 5 min at 5000 g to precip-
itate serum proteins. The supernatant was analyzed using RP-HPLC on a C18 reversed-phase column (Alltima; 
4.6 mm × 25 cm; Grace, Breda, The Netherlands) and ITLC. The column was eluted with a linear gradient of 0.1% 
TFA (trifluoroacetic acid, Lab-Scan, Analytical Sciences, Brussels, Belgium) in acetonitrile (3% to 100% over 
10 min) with a flow rate of 1 ml/min. ITLC was performed as described above.
Cell culture. The rat insulinoma cell line INS-147 was maintained in RPMI-1640 medium supplemented with 
10% fetal bovine serum, 2 mM glutamine, 10 mM HEPES, 50 µM β-mercaptoethanol, 1 mM sodium pyruvate, 
100 units/ml penicillin and 100 µg/ml streptomycin, in a humidified 5% CO2 atmosphere at 37 °C. The cells were 
harvested by trypsinization with trypsin/EDTA.
IC50 determination. The 50% inhibitory concentration (IC50) of maxadilan, DTPA-maxadilan, 
maxadilan-DTPA, 115In-DTPA-maxadilan and maxadilan-DTPA-115In was determined using suspensions 
Table 3. Amino acid sequences of maxadilan, DTPA-maxadilan and maxadilan-DTPA. Cysteine residues that 
form disulfide bonds are underlined and indicated by the dotted lines30.
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of INS-1 cells. Labeling of DTPA-maxadilan and maxadilan-DTPA with natIn was performed as previously 
described9, 48. Unlabeled and 115In-labeled peptides were added to the cells (approximately 10 × 106 cells in a 
final volume of 0.5 mL) in eppendorf tubes to final concentrations ranging from 0.1 to 300 nmol (n = 3) together 
with 1,000 Bq maxadilan-DTPA-111In. After 4 h incubation on ice, the cells were centrifuged at 3,000 × g, the 
supernatant was removed and the cells were washed with 1 ml ice-cold PBS and the radioactivity in the cell pellet 
was determined in a well-type gamma counter (Wallac 1480-Wizard, Perkin-Elmer, Boston, MA, USA). The IC50 
value was calculated by one-site competition analysis with Graphpad Prism (version 5.03, GraphPad Software, 
San Diego, CA USA).
Biodistribution studies. All experiments were performed in accordance with Radboud University 
guidelines. Animal experiments were approved by the Animal Ethical Committee of the Radboud University, 
Nijmegen, The Netherlands.
In order to assess the feasibility of targeting insulinomas with radiolabeled maxadilan, female BALB/c 
nude mice (6–8 weeks old) were injected subcutaneously with INS-1 cells (1 × 107 cells in 200 µl). When the 
tumors had grown to approximately 5 mm in diameter, groups of five mice were injected with either 370 kBq 
111In-DTPA-maxadilan or maxadilan-DTPA-111In (peptide dose: 13 pmol). For both peptides, an additional group 
of 5 mice was co-injected with an excess (1,300 pmol) of unlabelled maxadilan to determine the nonspecific 
binding of the peptides to the cells. Mice were euthanized 2 h p.i. and blood, muscle, tumor, heart, lung, spleen, 
pancreas, stomach, intestine, adrenals, kidney and liver were dissected, weighed and the radioactivity concentra-
tion was determined.
To examine the pharmacokinetics of maxadilan-DTPA-111In, BALB/c nude mice (n = 4/group) were injected 
with 370 kBq maxadilan-DTPA-111In and mice were euthanized at 1, 2 or 4 h p.i. The radioactivity concentration 
in the organs was measured in a gamma counter.
SPECT of BALB/c nude mice bearing subcutaneous INS-1 tumors. BALB/c nude mice bearing sub-
cutaneous INS-1 tumors were injected intravenously with 9 MBq maxadilan-DTPA-111In (13 pmol). A separate 
group of tumor-bearing mice was co-injected with an excess of unlabelled maxadilan (1,300 pmol). One and four 
h p.i. SPECT/CT images were acquired using a dedicated small animal SPECT scanner (U-SPECT-II, MILabs, 
Utrecht, The Netherlands). SPECT images were acquired with a 0.6 mm pinhole mouse collimator with an acqui-
sition time of 50 min. The images were reconstructed with OSEM (3 iterations, 16 subsets, voxel size 0.375) using 
the U-SPECT-Rec software (MILabs, Utrecht, The Netherlands). The settings for the CT were as follows: spatial 
resolution, 160 μm; 40 kV; 612 μA.
Statistical analysis. Statistical analysis was done using GraphPad Prism version 5.03 for Windows. The 
unpaired t test was used for determination of significance. A p-value below 0.05 was considered as significant. For 
the competitive binding assay the F-test was used to manually calculate significance.
References
 1. Iglesias, P. & Diez, J. J. Management of endocrine disease: a clinical update on tumor-induced hypoglycemia. European journal of 
endocrinology/European Federation of Endocrine Societies. 170, R147–157 (2014).
 2. Granberg, D. & Oberg, K. Neuroendocrine tumours. Cancer chemotherapy and biological response modifiers. 22, 471–483 (2005).
 3. Modlin, I. M. & Tang, L. H. Approaches to the diagnosis of gut neuroendocrine tumors: the last word (today). Gastroenterology. 112, 
583–590 (1997).
 4. Reubi, J. C. & Waser, B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo 
multireceptor tumour targeting. European journal of nuclear medicine and molecular imaging. 30, 781–793 (2003).
 5. Baumann, T., Rottenburger, C., Nicolas, G. & Wild, D. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and 
staging. Best practice & research. Clinical endocrinology & metabolism. 30, 45–57 (2016).
 6. Bodei, L. et al. The status of neuroendocrine tumor imaging: from darkness to light? Neuroendocrinology. 101, 1–17 (2015).
 7. Prasad, V. et al. Role of (68)Ga somatostatin receptor PET/CT in the detection of endogenous hyperinsulinaemic focus: an 
explorative study. European journal of nuclear medicine and molecular imaging. 43, 1593–1600 (2016).
 8. Sharma, P. et al. Somatostatin receptor based PET/CT imaging with 68 Ga-DOTA-Nal3-octreotide for localization of clinically and 
biochemically suspected insulinoma. The quarterly journal of nuclear medicine and molecular imaging: official publication of the 
Italian Association of Nuclear Medicine. 60, 69–76 (2016).
 9. Brom, M. et al. 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET. European journal of nuclear 
medicine and molecular imaging. 37, 1345–1355 (2010).
 10. Wild, D. et al. [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor 
targeting. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 47, 2025–2033 (2006).
 11. Wild, D. et al. Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT. Journal of 
nuclear medicine: official publication, Society of Nuclear Medicine. 51, 1059–1067 (2010).
 12. Christ, E. et al. Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging 
study. The lancet. Diabetes & endocrinology. 1, 115–122 (2013).
 13. Christ, E. et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. The Journal of clinical endocrinology and 
metabolism. 94, 4398–4405 (2009).
 14. Sowa-Staszczak, A. et al. Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC- 99mTc/EDDA)NH2]-exendin-4 for 
the detection of insulinoma. European journal of nuclear medicine and molecular imaging. 40, 524–531 (2013).
 15. Wild, D. et al. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. The New England journal of medicine. 359, 
766–768 (2008).
 16. Antwi, K. et al. Localization of Hidden Insulinomas with (6)(8)Ga-DOTA-Exendin-4 PET/CT: A Pilot Study. Journal of nuclear 
medicine: official publication, Society of Nuclear Medicine. 56, 1075–1078 (2015).
 17. Eriksson, O. et al. Detection of metastatic insulinoma by positron emission tomography with [(68)ga]exendin-4-a case report. The 
Journal of clinical endocrinology and metabolism. 99, 1519–1524 (2014).
 18. Christ, E., Wild, D. & Reubi, J. C. Glucagonlike peptide-1 receptor: an example of translational research in insulinomas: a review. 
Endocrinology and metabolism clinics of North America. 39, 791–800 (2010).
www.nature.com/scientificreports/
8Scientific RepoRts | 7: 1751  | DOI:10.1038/s41598-017-01852-8
 19. Wild, D. et al. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. 
Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 52, 1073–1078 (2011).
 20. Inagaki, N., Kuromi, H. & Seino, S. PACAP/VIP receptors in pancreatic beta-cells: their roles in insulin secretion. Annals of the New 
York Academy of Sciences. 805, 44–51 (1996). discussion 52–43.
 21. Moody, T. W., Nuche-Berenguer, B. & Jensen, R. T. Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, 
and their receptors and cancer. Current opinion in endocrinology, diabetes, and obesity. 23, 38–47 (2016).
 22. Tatsuno, I. et al. Maxadilan specifically interacts with PAC1 receptor, which is a dominant form of PACAP/VIP family receptors in 
cultured rat cortical neurons. Brain research. 889, 138–148 (2001).
 23. Borboni, P. et al. Molecular and functional characterization of pituitary adenylate cyclase-activating polypeptide (PACAP-38)/
vasoactive intestinal polypeptide receptors in pancreatic beta-cells and effects of PACAP-38 on components of the insulin secretory 
system. Endocrinology. 140, 5530–5537 (1999).
 24. Ahren, B. Role of pituitary adenylate cyclase-activating polypeptide in the pancreatic endocrine system. Annals of the New York 
Academy of Sciences. 1144, 28–35 (2008).
 25. Arimura, A. Pituitary adenylate cyclase activating polypeptide (PACAP): discovery and current status of research. Regulatory 
peptides. 37, 287–303 (1992).
 26. Arimura, A. & Shioda, S. Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors: neuroendocrine and 
endocrine interaction. Frontiers in neuroendocrinology. 16, 53–88 (1995).
 27. Lerner, E. A., Ribeiro, J. M., Nelson, R. J. & Lerner, M. R. Isolation of maxadilan, a potent vasodilatory peptide from the salivary 
glands of the sand fly Lutzomyia longipalpis. The Journal of biological chemistry. 266, 11234–11236 (1991).
 28. Moro, O. & Lerner, E. A. Maxadilan, the vasodilator from sand flies, is a specific pituitary adenylate cyclase activating peptide type I 
receptor agonist. The Journal of biological chemistry. 272, 966–970 (1997).
 29. Lerner, E. A., Iuga, A. O. & Reddy, V. B. Maxadilan, a PAC1 receptor agonist from sand flies. Peptides. 28, 1651–1654 (2007).
 30. Moro, O. et al. Functional characterization of structural alterations in the sequence of the vasodilatory peptide maxadilan yields a 
pituitary adenylate cyclase-activating peptide type 1 receptor-specific antagonist. The Journal of biological chemistry. 274, 
23103–23110 (1999).
 31. Vamos, Z. et al. Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Induces Relaxations of Peripheral and Cerebral 
Arteries, which are Differentially Impaired by Aging. Journal of molecular neuroscience: MN. 54, 535–542 (2014).
 32. Yada, T. et al. Pituitary adenylate cyclase activating polypeptide is an extraordinarily potent intra-pancreatic regulator of insulin 
secretion from islet beta-cells. The Journal of biological chemistry. 269, 1290–1293 (1994).
 33. Kiesewetter, D. O. et al. 18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma. European journal of nuclear 
medicine and molecular imaging. 39, 463–473 (2012).
 34. Rylova, S. N. et al. Approaches to Improve the Pharmacokinetics of Radiolabeled Glucagon-Like Peptide-1 Receptor Ligands Using 
Antagonistic Tracers. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 57, 1282–1288 (2016).
 35. Prasad, V. et al. Role of Ga somatostatin receptor PET/CT in the detection of endogenous hyperinsulinaemic focus: an explorative 
study. European journal of nuclear medicine and molecular imaging (2016).
 36. Reubi, J. C. & Waser, B. Triple-peptide receptor targeting in vitro allows detection of all tested gut and bronchial NETs. Journal of 
nuclear medicine: official publication, Society of Nuclear Medicine. 56, 613–615 (2015).
 37. van der Zwan, W. A. et al. GEPNETs update: Radionuclide therapy in neuroendocrine tumors. European journal of endocrinology/
European Federation of Endocrine Societies. 172, R1–8 (2015).
 38. Zeng, N. et al. PACAP type I receptor activation regulates ECL cells and gastric acid secretion. The Journal of clinical investigation. 
104, 1383–1391 (1999).
 39. Zeng, N. et al. The pituitary adenylate cyclase activating polypeptide type 1 receptor (PAC1-R) is expressed on gastric ECL cells: 
evidence by immunocytochemistry and RT-PCR. Annals of the New York Academy of Sciences. 865, 147–156 (1998).
 40. Cavallaro, A. et al. The role of 68-Ga-DOTATOC CT-PET in surgical tactic for gastric neuroendocrine tumors treatment: our 
experience: a case report. International journal of surgery. 12(Suppl 1), S225–231 (2014).
 41. Kalmbach, N. et al. Molecular and functional characterization of PACAP/VIP receptors in Lewis lung carcinoma cells. Pneumologie. 
66, A604 (2012).
 42. Reubi, J. C. et al. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and 
their tissues of origin. Cancer research. 60, 3105–3112 (2000).
 43. Robberecht, P. et al. Receptors for pituitary adenylate cyclase activating peptides in human pituitary adenomas. The Journal of clinical 
endocrinology and metabolism. 77, 1235–1239 (1993).
 44. Robberecht, P. et al. Expression of pituitary adenylate cyclase activating polypeptide (PACAP) receptors in human glial cell tumors. 
Peptides. 15, 661–665 (1994).
 45. Vertongen, P. et al. Pituitary adenylate cyclase activating peptide and its receptors are expressed in human neuroblastomas. Journal 
of cellular physiology. 167, 36–46 (1996).
 46. Busto, R. et al. VIP and PACAP receptors coupled to adenylyl cyclase in human lung cancer: a study in biopsy specimens. Peptides. 
24, 429–436 (2003).
 47. Asfari, M. et al. Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines. Endocrinology. 130, 
167–178 (1992).
 48. Brom, M. et al. Radiolabelled GLP-1 analogues for in vivo targeting of insulinomas. Contrast media & molecular imaging. 7, 160–166 
(2012).
Acknowledgements
We would like to thank J.K. Sosabowski (Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary 
University of London) for her help with editing the manuscript.
Author Contributions
L.J., M.B., O.B. and M.G. contributed in the design of the study, M.S. and E.W. contributed to the new compound, 
L.J. and M.B. performed the experiments and analyzed the data, L.J. wrote the manuscript, M.S., E.W., and M.B. 
contributed to the introduction and discussion. All authors reviewed and edited the manuscript.
Additional Information
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
www.nature.com/scientificreports/
9Scientific RepoRts | 7: 1751  | DOI:10.1038/s41598-017-01852-8
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
